Josh Jennings has given his Buy rating due to a combination of factors that demonstrate Medtronic's strong financial performance and promising outlook. In particular, the company's first-quarter non-GAAP revenue and EPS surpassed both the guidance and the Street's expectations, with a reported $8.00 billion in revenue and $1.23 in earnings per share. The organic sales growth rate of 5.3% notably exceeded the projected range of 4-4.5%, and Medtronic raised its future organic sales growth outlook to 4.5-5% from the previous 4-5%. Additionally, Medtronic's EPS target was adjusted to a higher range, reflecting confidence in the company's earnings potential. Moreover, three out of Medtronic's four business segments experienced growth that surpassed analyst expectations, indicating robust performance across a diversified portfolio. The company's notable gross and operating margins showcased strong profitability, contributing to the positive recommendation.